Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest American Association for Cancer Research Stories

2011-12-08 12:53:09

Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who received the combination therapy with placebo. Researchers conducted an international phase 3, double-blind, randomized trial, known as CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab), in which they randomly assigned 808 patients to receive trastuzumab and...

2011-12-08 12:51:26

Results from a German study demonstrated no improvement in disease-free survival among patients with breast cancer who were treated with dose-dense chemotherapy and the bisphosphonate ibandronate. Volker Möbus, Ph.D., head of the department of obstetrics and gynecology at Klinikum Frankfurt Höchst GmbH in Frankfurt, presented the results from the German Adjuvant Intergroup Node Positive (GAIN) Study, at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held...

2011-12-08 12:50:17

A recently presented study revealed that the bisphosphonate clodronate had a low incidence of adverse events and toxicity among patients with breast cancer and may modestly reduce the incidence of distant metastases in postmenopausal women. The results of B-34, a prospective, randomized, double-blind, phase 3 clinical trial, presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011, are similar to those of trials on other bisphosphonates in this group of...

2011-12-07 21:36:01

The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced the risk for disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer, according to new data from the ZO-FAST trial. Richard de Boer, M.D., of the Royal Melbourne Hospital in Victoria, Australia, presented long-term data from the Zometa-Femara Adjuvant Synergy Trial (ZO-FAST) trial at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held...

2011-12-07 21:34:36

Researchers have proven the continuing effectiveness of treating patients with estrogen receptor-positive premenopausal breast cancer with adjuvant zoledronic acid in addition to adjuvant endocrine treatment including ovarian function suppression. Data from the Austrian Breast & Colorectal Cancer Study Group (ABCSG-12), reported at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011, confirmed and extended data reported at 48 months and 62 months of follow-up....

2011-12-07 11:01:56

In a significant advance for patients with ductal carcinoma in situ, researchers have developed and prospectively validated a multigene test to identify the risk for recurrence of breast cancer. The method combines measuring tumor gene expression with a gene expression algorithm to decipher the genetic underpinnings of a patient's cancer and determine whether the individual patient should be treated with surgery (usually lumpectomy) or a combination of surgery and radiation. This is the...

2011-12-07 10:48:05

Compared with women treated with whole-breast irradiation, women treated with brachytherapy experienced a twofold increased risk for losing their breasts, according to findings presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011. Benjamin D. Smith, M.D., assistant professor in the department of radiation oncology at MD Anderson Cancer Center in Houston, and colleagues evaluated the Medicare claims of all U.S. female beneficiaries (n=130,535) aged older...

2011-12-07 10:46:49

Researchers may have discovered a series of genes that will help predict whether or not a woman with hormone receptor-positive invasive breast cancer will experience early, late or no recurrence of her disease. Minetta C. Liu, M.D., associate professor of medicine and oncology and director of translational breast cancer research at Georgetown Lombardi Comprehensive Cancer Center, presented the findings at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011....

2011-12-07 10:43:46

Having diabetes or being obese after age 60 significantly increases the risk for developing breast cancer, a Swedish study has revealed. Data also showed that high blood lipids were less common in patients when diagnosed with breast cancer, while low blood lipids were associated with an increased risk. Researchers of the study, reported at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011, also looked at overall cancer incidence and discovered that use of one...

2011-12-06 23:25:40

A new case-control study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, shows that women who participated in at least three screening mammograms had a 49 percent lower risk for breast cancer mortality. "Our study adds further evidence that mammography screening unambiguously reduces breast cancer mortality," said Suzie Otto, Ph.D., a senior researcher in the department of public health at the Erasmus MC at Rotterdam...